Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Divestments (2021 - 2024)

BioNexus Gene Lab's Divestments history spans 4 years, with the latest figure at $197063.0 for Q3 2024.

  • For Q3 2024, Divestments changed N/A year-over-year to $197063.0; the TTM value through Sep 2024 reached $297707.0, changed N/A, while the annual FY2023 figure was $61409.0, 46.78% down from the prior year.
  • Divestments for Q3 2024 was $197063.0 at BioNexus Gene Lab, up from $11096.0 in the prior quarter.
  • Across five years, Divestments topped out at $197063.0 in Q3 2024 and bottomed at $7230.0 in Q1 2022.
  • The 4-year median for Divestments is $11594.0 (2022), against an average of $42598.6.
  • The largest annual shift saw Divestments skyrocketed 844.69% in 2022 before it dropped 8.24% in 2023.
  • A 4-year view of Divestments shows it stood at $8559.0 in 2021, then surged by 844.69% to $80856.0 in 2022, then tumbled by 86.28% to $11096.0 in 2023, then skyrocketed by 1675.98% to $197063.0 in 2024.
  • Per Business Quant, the three most recent readings for BGLC's Divestments are $197063.0 (Q3 2024), $11096.0 (Q2 2023), and $8692.0 (Q1 2023).